Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

GermanyBack to Germany

Clinical trials in Cologne – page 24

639 clinical trials in Cologne, Germany across 4 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Cologne at a glance
639
clinical trials
  • Research sites4
Type of trial
Recruitment status
Quick filters

639 trials in Cologne

Open in trial search

C3 glomerulopathy

Not yet recruiting

Pegcetacoplan to Prevent Recurrence of C3 Glomerulopathy or Primary Immune‑Complex MPGN in Adolescent and Adult Kidney Transplant Recipients

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Pegcetacoplan
  • Sponsor:Swedish Orphan Biovitrum AB (publ)

Study of setidegrasib (ASP3082) and docetaxel in patients with KRAS G12D‑mutated advanced/metastatic NSCLC after platinum chemo and checkpoint inhibitor

Not yet recruiting
Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:ASP3082
  • Sponsor:Astellas Pharma Global Development Inc.

Non-small cell lung cancer

Not yet recruiting

Pembrolizumab alone versus pembrolizumab with chemotherapy drug combination in women with advanced non‑small cell lung cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts

Metastatic malignant melanoma+2

Not yet recruiting

Methoxsalen (ECP) versus drug combination for steroid‑refractory immune‑related colitis or hepatitis in metastatic melanoma on checkpoint therapy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Azathioprine

Hodgkin's disease

Not yet recruiting

Phase II Study of Brentuximab Vedotin with Drug Combination in HIV‑Positive Patients with Advanced‑Stage Classic Hodgkin Lymphoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Brentuximab Vedotin
  • Sponsor:University Of Cologne

Prostate cancer

Not yet recruiting

Phase 1 Study of Terbium (161TB) Zadavotide Guraxetan as Neoadjuvant Treatment in Very High‑Risk Prostate Cancer Patients Eligible for Surgery

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years

A Phase III study of AZD0120 with drug combination versus standard therapy in adults with newly diagnosed multiple myeloma not eligible for stem cell transplant

Not yet recruiting
Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:AZD0120
  • Sponsor:AstraZeneca AB

Stargardt's disease

Not yet recruiting

Phase 3 Study of Gildeuretinol Acetate (ALK‑001) to Assess Safety and Efficacy in Slowing Progression of Stargardt Disease in Adults

Investigational
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years

Non-small cell lung cancer+1

Not yet recruiting

Phase 1/2 Study of Oral TRI-611 in Adults With Advanced ALK‑Positive Non‑Small Cell Lung Cancer

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years

Enterococcal infection

Not yet recruiting

Effectiveness and Safety of INTESTIFIX in Removing Vancomycin‑Resistant Enterococci Colonization in Immunocompromised Patients – drug combination

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Ascorbic Acid
  • Sponsor:Fraunhofer Institute For Translational Medicine And Pharmacology ITMP

B precursor type acute leukaemia

Not yet recruiting

Phase II study of autologous enriched T‑cell therapy expressing CD19 and CD22 CARs in Philadelphia‑negative B‑precursor ALL patients with measurable residual disease

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Autologous Enriched T Cells Retrovirally Transduced To Express Two Chimeric Antigen Receptors Targeting Cd19 And Cd22
  • Sponsor:Goethe University Frankfurt

COVID-19

Not yet recruiting

Study of nirmatrelvir and remdesivir to achieve viral clearance in immunocompromised patients with persistent COVID-19

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Nirmatrelvir
  • Sponsor:Goethe University Frankfurt

Other cities in Germany

The busiest research cities in the country

All 518 cities in Germany

Clinical research in Cologne

What the registry says about research in the country

01 Oncology Research

Innovative clinical trials focusing on advanced cancer treatments, including studies for diffuse large B-cell lymphoma, multiple myeloma, and various solid tumors. Research aims to evaluate new combination therapies and targeted treatments.

  • Lymphoma and Blood Cancers
  • Advanced Breast Cancer
  • Non-Small Cell Lung Cancer

Multiple studies are investigating novel drug combinations and immunotherapy approaches.

02 Autoimmune Conditions

Comprehensive research into autoimmune disorders, with particular focus on Sjögren's Disease and rheumatoid arthritis. Studies evaluate new biological therapies and treatment approaches.

  • Inflammatory Myopathies
  • Primary Sjögren's Disease
  • Rheumatic Diseases

Trials aim to improve disease management and patient outcomes through innovative therapies.

03 Infectious Diseases

Groundbreaking research in infectious disease management, including studies on HIV-1 treatment and drug-resistant infections. Focus on developing new therapeutic approaches and treatment strategies.

  • HIV Treatment Innovation
  • Antimicrobial Resistance
  • Pneumococcal Disease

Studies explore novel treatment regimens and preventive approaches.

Back to GermanyAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.